RAREHealthcare · Biotechnology

RARE Stock Forecast: Ultragenyx Pharmaceutical, Inc. Price Predictions for 2026-2027

Last close, 24 Sept 2026

$15

−0.74% on the day

The 20 Wall Street analysts covering Ultragenyx Pharmaceutical, Inc. hold a median 12-month price target of $28 — +89.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 23 Sept 2026 — in the lower half.

Market cap

$1.5B

Ticker Nerd rank

46 / 100

Median analyst target

$28

Analysts covering

Revenue$214.0M+28.5% y/y

Operating income−$75.0M

Net income−$92.0M

Free cash flow−$98.0M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+1.9%

−42.6%

YTD

−35.8%

−48.6%

From 52W high

−59.6%

From 52W low

+14.7%

$13

$37

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

RARE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ultragenyx Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026

46 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value

Revisions

Accruals

Quality

Volatility

Growth

Size

Momentum

Issuance

Value (81): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RARE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RARE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says20 analysts

11 Buy9 Hold0 Sell

Low $18Median $28High $40

The green dot is the last close — the median target sits +89.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 13 moved it down.

Date	Firm	Action	Rating	Target
21 Sept 2026	Barclays	Maintains	Overweight	$32 → $35
21 Sept 2026	Evercore ISI Group	Maintains	In-Line	$16 → $18
18 Sept 2026	Canaccord Genuity	Maintains	Buy	$37 → $39
18 Sept 2026	Cantor Fitzgerald	Maintains	Overweight	$33 → $39
18 Sept 2026	Citigroup	Maintains	Buy	$31 → $32
18 Sept 2026	Morgan Stanley	Maintains	Equal-Weight	$18 → $20
17 Sept 2026	Citigroup	Maintains	Buy	$28 → $31
4 Sept 2026	Barclays	Maintains	Overweight	$43 → $32
4 Sept 2026	Goldman Sachs	Maintains	Neutral	$28 → $19
3 Sept 2026	Baird	Downgrade	Neutral	$40 → $16
3 Sept 2026	Canaccord Genuity	Maintains	Buy	$83 → $37
3 Sept 2026	Cantor Fitzgerald	Maintains	Overweight	$103 → $33
3 Sept 2026	Citigroup	Maintains	Buy	$58 → $28
3 Sept 2026	Evercore ISI Group	Downgrade	In-Line	$34 → $16
3 Sept 2026	HC Wainwright & Co.	Maintains	Buy	$50 → $25
3 Sept 2026	Jefferies	Maintains	Buy	$77 → $28
3 Sept 2026	JP Morgan	Downgrade	Neutral	$80 → $36
3 Sept 2026	TD Cowen	Maintains	Buy	$49 → $18
3 Sept 2026	Wedbush	Maintains	Neutral	$30 → $23
3 Sept 2026	Wells Fargo	Maintains	Overweight	$50 → $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RARE appears on the weeks it earns a place.

Performance

RARE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, Ultragenyx Pharmaceutical, Inc. returned −48.6% against +17.3% for the S&P 500, dividends included.

RARE vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RARE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Ultragenyx Pharmaceutical, Inc. (RARE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −2.6×
Price / sales: 2.1×
Price / book: −5.4×
EV / EBITDA: −5.3×

Growth & margins

Revenue growth (YoY): 28.1%
Earnings growth (YoY): 28.5%
Gross margin: 84.1%
Operating margin: −35.0%
Net margin: −81.7%

Returns & dividend

Return on equity: 787.7%
Return on assets: −24.2%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ultragenyx Pharmaceutical, Inc. (RARE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Ultragenyx Pharmaceutical, Inc. has a market value of $1.5B and an enterprise value of $2.5B.
Revenue in the twelve months to 30 June 2026: $717.2M. The latest quarter grew 28.1% year on year.
Net income over the same four quarters: −$586.0M, a −81.7% net margin.
Diluted earnings per share, trailing twelve months: $−5.84.
Free cash flow in the twelve months to 30 June 2026: −$494.0M.
Shares outstanding: 98.6M.
Trailing P/E: −2.6×; forward P/E: 22.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Ultragenyx Pharmaceutical, Inc. employs 1,371 people — $523K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 23 Sept 2026

Data provided by Twelve Data

Peers

RARE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
RAREUltragenyx Pharmaceutical, Inc.	$1.5B	46
OMEROmeros Corp.	$1.5B	93
KRSAKorsana Biosciences, Inc.	$1.5B	37
INBXInhibrx Biosciences, Inc.	$1.5B	25
AVBPArrivent BioPharma, Inc.	$1.5B	38
ANABAnaptysBio, Inc.	$1.5B	94
INVAInnoviva, Inc.	$1.5B	86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ultragenyx Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RARE news & analysis

RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

Zacks Investment Research · 18 Sept 2026positive

Ultragenyx's stock rose 13% following the FDA's approval of Fayuvi, the first treatment approved for Sanfilippo syndrome Type A. The approval was supported by durable clinical data.

Why it matters — This marks a significant regulatory milestone for Ultragenyx, giving the company its first approved therapy for Sanfilippo syndrome Type A and a new commercial product in its pipeline.

Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?

Zacks Investment Research · 18 Sept 2026positive

Ultragenyx (RARE) shares surged 12.6% in the last session on higher-than-average trading volume. The article notes that the latest trend in earnings estimate revisions could support further gains in the near term.

Why it matters — A RARE watcher would care because the strong price move and favorable earnings estimate revision trend may signal growing investor confidence in the company's near-term prospects.

Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week

Benzinga · 18 Sept 2026positive

Abeona Therapeutics had a busy week that included activating a new treatment center, receiving an FDA approval for a drug it had licensed away (which entitles Abeona to royalties tied to Ultragenyx's approval), and drawing multiple fresh analyst ratings.

Why it matters — A RARE watcher would care because the FDA approval of a drug licensed from Abeona reflects a regulatory milestone in Ultragenyx's pipeline that also triggers royalty obligations.

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript

Seeking Alpha · 18 Sept 2026positive

The news item covers a Seeking Alpha transcript of Ultragenyx Pharmaceutical discussing the FDA approval of FAYUVI as the first treatment for Sanfilippo Syndrome Type A. It is an official discussion of the company's product approval.

Why it matters — A RARE watcher would care because this marks FDA approval of the first treatment for Sanfilippo Syndrome Type A, a significant product milestone for the company.

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

GlobeNewsWire · 17 Sept 2026positive

Ultragenyx announced that the FDA approved FAYUVI, its gene therapy which is the first-ever FDA-approved treatment for Sanfilippo syndrome Type A (MPS IIIA). The therapy has the potential to stop or slow the neurologic disease progression and loss of function associated with the condition.

Why it matters — This approval gives Ultragenyx a first-in-class commercial product for an untreated rare disease, potentially expanding its rare-disease portfolio and revenue base.

FAQ

Frequently asked questions about RARE stock

What is the RARE stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Ultragenyx Pharmaceutical, Inc. have a median 12-month price target of $28, with estimates ranging from $18 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RARE stock a buy right now?

Of the 20 analysts covering Ultragenyx Pharmaceutical, Inc., 11 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ultragenyx Pharmaceutical, Inc. 46 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RARE?

As at 23 Sept 2026, Ultragenyx Pharmaceutical, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (81 of 100).

Will RARE stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +89.6% from the last close, and Ticker Nerd's factor model ranks Ultragenyx Pharmaceutical, Inc. 46 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RARE stock forecast for 2030?

No analyst covering Ultragenyx Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RARE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $40 over the next 12 months.

How has RARE stock performed over the past year?

Ultragenyx Pharmaceutical, Inc. returned -48.6% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ultragenyx Pharmaceutical, Inc. do?

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases.

What is the latest news on RARE?

The most recent item we track (Zacks Investment Research, 18 Sept 2026): "RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy". Ultragenyx's stock rose 13% following the FDA's approval of Fayuvi, the first treatment approved for Sanfilippo syndrome Type A. The approval was supported by durable clinical data.

Company

About Ultragenyx Pharmaceutical, Inc.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Its current portfolio includes approved medicines and other therapies designed to address serious conditions with limited treatment options, spanning metabolic, skeletal, and other inherited disorders. The company works across multiple modalities, including biologics, small molecules, gene therapy, and nucleic acid-based approaches, to target diseases where the underlying biology is well understood and patient need is high. Ultragenyx serves patients through marketed products such as therapies for X-linked hypophosphatemia, long-chain fatty acid oxidation disorders, mucopolysaccharidosis, and homozygous familial hypercholesterolemia. Headquartered in Novato, California, Ultragenyx plays a specialized role in the rare-disease market by combining commercialization capabilities with ongoing research and development in genetic medicine.

CEO Dr. Emil D. Kakkis M.D., Ph.D. · 1,371 employees · United States · https://www.ultragenyx.com